Immunic to Participate in Scientific and Investor Conferences in March
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in March:
March 4-7: 34th Annual Meeting of the Society for Virology. Two abstracts have been accepted for abstract talk presentations at this conference in Hamburg, Germany. The presentations will be accessible on the 'Events and Presentations' section of Immunic's website at: https://ir.imux.com/events-and-presentations.
Title: Orally Bioavailable RORγ/DHODH Dual Host-Targeting Small Molecules with Broad-Spectrum Antiviral Activity
Presenting Author: Friedrich Hahn, Ph.D., Institute for Clinical and Molecular Virology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany
Abstract Talk: O 081
Session: Antiviral therapy and resistance I
Date: March 6, 2025
Time: 9:30-9:45 am CET (3:30-3:45am ET)
Title: Novel Vidofludimus-Based DHODH Inhibitors Containing Carboxylic Acid Bioisosters with Superior Broad-Spectrum Antiviral Activity
Presenting Author: Alexandra Herrmann, Ph.D., Manager Translational Pharmacology, Immunic
Abstract Talk: O 112
Session: Antiviral therapy and resistance II
Date: March 7, 2025
Time: 11:00-11:15am CET (5:00-5:15am ET)
March 10-12: Leerink Partners Global Healthcare Conference. Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in a fireside chat on Wednesday, March 12, at 10:00 am ET during this conference in Miami. A webcast will be available on the 'Events and Presentations' section of Immunic's website at: https://ir.imux.com/events-and-presentations.
Dr. Vitt, Glenn Whaley, Chief Financial Officer, and Jessica Breu, Vice President Investor Relations and Communications, will also participate in one-on-one investor meetings at the conference. To schedule a meeting, please contact your Leerink representative or Jessica Breu at: [email protected].
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 and phase 2 clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis and moderate-to-severe ulcerative colitis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease as well as inflammatory bowel disease, Graft-versus-Host-Disease and weight management. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: www.imux.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains 'forward-looking statements' that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in scientific and investor conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, increasing inflation, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, including the ability to satisfy the minimum average price and trading volume conditions required to receive funding in tranche 2 and 3 of the January 2024 private placement, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the Company's products or product candidates, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned 'Risk Factors,' in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on February 22, 2024, and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.
Contact Information
Immunic, Inc.
+49 89 2080 477 09
[email protected]
US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
[email protected]
US Media Contact
KCSA Strategic Communications
Caitlin Kasunich
+1 212 896 1241
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Casey's General Stores Inc (CASY) Q4 2025 Earnings Call Highlights: Record Profits and ...
Diluted Earnings Per Share: $14.64, a 9% increase from the prior year. Net Income: $547 million, a record figure. EBITDA: $1.2 billion, an increase of 13% from the prior year. Total Inside Sales Growth: 10.9% for the fiscal year. Inside Same Store Sales Growth: 2.6% or 7.1% on a two-year stack basis. Prepared Food and Dispensed Beverage Sales Growth: 10.3% total, with same store sales up 3.5% or 10.5% on a two-year stack basis. Grocery and General Merchandise Sales Growth: 11.2% total, with same store sales up 2.3% or 5.8% on a two-year stack basis. Inside Margin: Expanded 50 basis points to 41.5% year over year. Fuel Gross Profit: Up 11%, with total fuel gallons sold up 13% and a fuel margin averaging $0.387 per gallon. Same Store Operating Expenses: Excluding credit card fees, up 1.7% for the year. Store Growth: 35 new builds and 235 units acquired, including 198 CEFCO convenience stores from the Fikes Wholesale acquisition. Free Cash Flow: $585 million for the fiscal year. Return on Invested Capital: 11.5%, down 60 basis points due to the Fikes acquisition. Dividend Increase: 14% increase to $0.57 per share, marking the 26th consecutive year of dividend growth. Warning! GuruFocus has detected 5 Warning Signs with GBGPF. Release Date: June 10, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Casey's General Stores Inc (NASDAQ:CASY) achieved a record year for diluted earnings per share, reaching $14.64, a 9% increase from the prior year. The company reported a record $547 million in net income and $1.2 billion in EBITDA, marking a 13% increase from the previous year. Fiscal 2025 was the largest store growth year in the company's history, with 35 new builds and 235 units acquired, including the significant Fikes Wholesale acquisition. Total inside sales grew by 10.9%, with prepared food and dispensed beverage sales increasing by 10.3%, and grocery and general merchandise sales rising by 11.2%. Fuel gross profit increased by 11%, with total fuel gallons sold up 13% and a fuel margin averaging $0.387 per gallon over the year. The integration of the Fikes acquisition presents challenges, with some synergies, particularly in procurement and kitchen installations, not expected to be realized until after fiscal 2026. Same store operating expenses, excluding credit card fees, increased by 1.7%, with insurance expenses contributing to the rise. Net interest expense rose to $27.9 million, primarily due to financing associated with the Fikes transaction. The effective tax rate increased to 23% from 22.4% in the prior year, due to a slight decrease in favorable permanent differences. The company faces a $0.02 per gallon headwind due to the CEFCO stores, impacting overall fuel margins. Q: Fuel margins came in better than expected despite the CEFCO headwind. Can you discuss progress on synergies and expectations for fiscal '26? A: Darren Rebelez, CEO: Our team managed the fuel pricing environment well, capturing more margin due to fluctuations in wholesale costs. Progress in upstream fuel procurement also contributed to stronger margins. We expect the $0.02 CEFCO headwind to persist throughout fiscal '26. Q: Can you unpack the 41% combined inside margins for grocery and prepared foods? A: Steve Bramlage, CFO: The Fikes acquisition will put downward pressure on margins, especially in prepared foods due to their lack of pizza business. However, product mix enhancements and strong performance in categories like non-alcoholic beverages and nicotine alternatives are offsetting this pressure. Q: What is the outlook for same-store sales in fiscal '26, and can you elaborate on the wings test? A: Darren Rebelez, CEO: We are comfortable with the 2% to 5% range, factoring in some conservatism due to global uncertainties. The wings test in 225 stores is showing encouraging results, with strong guest feedback, but it's still in the testing phase. Q: How is the illicit vape market impacting your sales, and what are you doing about it? A: Darren Rebelez, CEO: The illicit vape market is impacting the vape category, leading to declines. We are working with tobacco manufacturers to increase enforcement. However, nicotine alternatives, especially pouches, are growing, with a 54% increase in sales due to merchandising efforts. Q: Can you discuss the pace of kitchen installations at acquired CEFCO stores and the supply contract timeline? A: Darren Rebelez, CEO: We haven't built in any kitchen conversions for this fiscal year due to permitting timelines. The existing supply contract with CEFCO stores ends in 2026, and we are working with the incumbent supplier on this agreement. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
24 minutes ago
- Yahoo
Why Space Stock Rocket Lab Soared Today
President Trump threatened last week to take away "governmental subsidies and contracts" from SpaceX. Investors may be wondering now who will end up with those subsidies and contracts, if SpaceX loses them. Rocket Lab seems a prime beneficiary of any such move. 10 stocks we like better than Rocket Lab › Rocket Lab (NASDAQ: RKLB) stock jumped 5.5% Monday afternoon on no obviously good news -- at least nothing specific to Rocket Lab. Despite the lack of news, The Fly is reporting "bullish flow" in the space stock, with call options buying outweighing put options purchases by nearly 5 to 1. So what's going on with Rocket Lab stock today? Most likely, the reason Rocket Lab is performing so well today is that another space stock is getting into some trouble. Over in Washington, D.C., you see, President Donald Trump and (ex-?) close advisor Elon Musk had a falling out last week, leading to the president threatening to "terminate Elon's governmental subsidies and contracts." And the seeming implication of this statement is that billions of dollars of government contracts hiring Musk's SpaceX to ferry astronauts and supplies to the International Space Station, to operate Starlink satellites for the Pentagon, and to build human landing systems for the moon, could now be up for grabs. Was the president's post on social media site Truth Social just bluster, or something more serious? No one knows for sure, but just the chance that billions of dollars of space work might open up to new bidders seems to be making Rocket Lab stock more valuable today. Still, a few words of caution are in order. On the one hand, the chance that Rocket Lab might steal some space contracts from SpaceX does seem a reasonable reason to bid up shares of Rocket Lab stock, but this is speculative. On the other hand, Rocket Lab's very expensive valuation is a present-day, verifiable fact. Lacking profits and trading for a heady 31 times sales valuation, I'd be cautious about buying more Rocket Lab stock until the price comes down a bit. Before you buy stock in Rocket Lab, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Rocket Lab wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Rich Smith has positions in Rocket Lab. The Motley Fool has positions in and recommends Rocket Lab. The Motley Fool has a disclosure policy. Why Space Stock Rocket Lab Soared Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29 minutes ago
- Yahoo
Brand Engagement Network Inc (BNAI) Q1 2025 Earnings Call Highlights: Strategic Partnerships ...
General and Administrative Expenses: Reduced by close to 50% compared with Q1 of last year. Line of Credit: Secured a $3.5 million line of credit from Core Capital Partners. Release Date: June 10, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Brand Engagement Network Inc (NASDAQ:BNAI) launched the iSkye platform, which has gained strong early traction across multiple industries. The company formed a significant partnership with Swiss Life Global Solutions to deliver AI-powered solutions, enhancing their global network. BNAI announced a partnership with Seven Visions Resort & Places to demonstrate AI capabilities in the hospitality sector. The company is collaborating with Valio Technologies and the University of KwaZulu-Natal on an AI-powered mental health program. BNAI has reduced general and administrative expenses by nearly 50% compared to the previous year, showcasing improved operational discipline. Revenue contributions from pilot programs are currently small and not yet significant. The company got a late start in the automotive sector, which may delay potential revenue from this vertical. There is uncertainty regarding the conversion of pilot programs into production contracts in the near term. Despite partnerships and collaborations, the company has yet to secure large household names as customers. The financial update indicates a reliance on a $3.5 million line of credit for additional financial flexibility. Warning! GuruFocus has detected 4 Warning Signs with BNAI. Q: What contributed to revenue in the quarter? Was it from pilot programs or production contracts? A: Paul Chang, CEO: All of our pilots are paid, contributing to revenue, but the scope and duration are short, so the revenue impact is not significant yet. Q: Of the various collaborations, do you have visibility into which may lead to production contracts soon? A: Paul Chang, CEO: In healthcare and life sciences, we anticipate some pilots converting to production deployments. In the automotive sector, despite a late start, we are optimistic about launching pilots and converting them into production this year due to strong relationships and technology adoption. Q: Can you provide more clarity on the automotive rollout, particularly with the partnership? A: Paul Chang, CEO: We have identified a high-value use case for dealerships and consumers. Technical integration and testing are complete, and we are deploying it as a pilot for a few dealers. We are also working with a large OEM on different use cases that benefit both OEMs and dealers. Q: What is the status of your partnerships in the automotive sector? A: Paul Chang, CEO: We have strong relationships with an OEM and large dealership networks. Our integration with is progressing well, and we are confident in our ability to convert pilots into production deployments this year. Q: How is the company managing its expenses and financial flexibility? A: Walid Khiari, CFO and COO: We reduced general and administrative expenses by nearly 50% compared to last year. We secured a $3.5 million line of credit from Core Capital Partners, providing additional financial flexibility. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
